SCHEMBL8323639

SCHEMBL8323639

O=C(Nc1ccc2ncccc2c1)c1ccc(-c2cnc3[nH]cc(-c4cn[nH]c4)c3c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MAPK9 P45984 2/20 0.52
POLB P06746 1/20 0.52
MAPK8 P45983 1/20 0.52
MAPK10 P53779 1/20 0.52
DYRK1A Q13627 7/20 0.49
CLK1 P49759 6/20 0.49
MMP9 P14780 2/20 0.49
AXL P30530 4/20 0.48
SGK1 O00141 3/20 0.48
CAMKK2 Q96RR4 2/20 0.48
DYRK1B Q9Y463 4/20 0.47
PRKD3 O94806 2/20 0.47
MAP4K4 O95819 2/20 0.47
EGFR P00533 2/20 0.47
NTRK1 P04629 2/20 0.47
FLT4 P35916 2/20 0.47
FLT3 P36888 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8322030 0.85 DYRK1A (0.58) NPC1RAB9AMAPK9MAPK8MAPK10
SCHEMBL8320090 0.84 AXL (0.62) MAPK9MAPK8MAPK10DYRK1ACLK1
SCHEMBL8313904 0.83 DYRK1A (0.56) MAPK9MAPK8MAPK10DYRK1ACLK1
SCHEMBL8313409 0.81 AXL (0.58) MAPK9MAPK8MAPK10DYRK1ACLK1
SCHEMBL12829935 0.80 MAPK8 (0.50) NPC1RAB9AMAPK9MAPK8MAPK10
SCHEMBL12829943 0.80 MAPK8 (0.50) MAPK9MAPK8MAPK10DYRK1ACLK1
SCHEMBL13746370 0.80 KIT (0.52) NPC1RAB9AMAPK9MAPK8MAPK10
SCHEMBL8320015 0.78 MAPK8 (0.65) MAPK9MAPK8MAPK10DYRK1ACLK1
SCHEMBL3765166 0.77 AXL (0.70) MAPK9MAPK8DYRK1AAXLSGK1
SCHEMBL8281985 0.77 DYRK1A (0.53) PABPC1NPC1RAB9APOLBDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295433-A2 JNK inhibitors Eisai R&D Management Co., Ltd. (JP) 2011-03-16 EP disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 PABPC1 3181/4885NPC1 695/4885RAB9A 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.